Rise Advisors’s Annovis Bio ANVS Stock Holding History

Rise Advisors’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-333	Closed	-$689	–	179
2025 Q3	$689	Hold	333	–	–	﹤0.01%	1332
2025 Q2	$723	Buy	+333	New	+$657	﹤0.01%	1337

Other funds holding ANVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Rise Advisors's ANVS Position: Q4 2025 in Review

Rise Advisors sold out of Annovis Bio (ANVS) in Q4 2025, closing a stake of 333 shares — an estimated $689 sold.

Rise Advisors first reported a position in ANVS in Q2 2025 and held it in 2 quarters. The position peaked at $723 in Q2 2025. 53 funds tracked by Wall St. Rank hold ANVS as of Q4 2025.

Rise Advisors reported no remaining Annovis Bio position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 333 Annovis Bio shares in Q4 2025, an estimated $689.
Rise Advisors first reported a position in Annovis Bio in Q2 2025 and held it in 2 quarters.
Rise Advisors's Annovis Bio position peaked at $723 in Q2 2025.
53 funds tracked by Wall St. Rank held Annovis Bio as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.